Taurine 3 pp 377-383 | Cite as

Treatment of Rat Brain Membranes with Taurine Increases Radioligand Binding

  • Pattie Green
  • Ralph DawsonJr.
  • David R. Wallace
  • Jeannie Owens
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 442)


Taurine is known to have numerous actions to modulate membrane stability and function9. Taurine has also been proposed to have antioxidant functions and several studies have demonstrated that taurine can attenuate lipid peroxidation caused by various toxic insults22. Our laboratory has studied the protective effects of taurine against oxidative stress caused by metal-stimulated catecholamine oxidation5. Taurine was shown to protect proteins from oxidative damage in both in vitro and in vivo experiments5. We previously observed in pilot studies that taurine could prevent the loss of dopamine receptors caused by exposing tissue homogenates to ferric chloride and dopamine6. We hypothesized that taurine might function to protect receptor proteins from oxidative damage. We also noted in these pilot studies that taurine alone in the absence of any oxidative damage could enhance radioligand binding.


NMDA Receptor Channel Related Amino Acid Cortical Membrane MK801 Binding Cortical Homogenate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bradford, M.M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72:248–254.PubMedCrossRefGoogle Scholar
  2. 2.
    Bureau, M.H. and Olsen, R.W., 1991, Taurine acts on a subclass of GABAA receptors in mammalian brain in vitro, Eur. J. Pharmacol., 207:9–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Bylund, D.B. and U’Prichard, D.C., 1983, Characterization of α1-and α2-adrenergic receptors, Intl. Rev. Neurobiol., 24:343–431.CrossRefGoogle Scholar
  4. 4.
    Dawson, R. and Oparil, S., 1987, Renal catecholamines and α2-adrenergic receptors in salt-related and genetic hypertension, Pharmacology, 34:131–142.PubMedCrossRefGoogle Scholar
  5. 5.
    Dawson, R., Tang, E., Shih, D., Hern, H., Hu, M., Baker, D., and Eppler, B., in press, Taurine inhibition of iron-stimulated catecholamine oxidation, in Adv. Exp. Med. Biol. “Taurine....”,. Huxtable, R., Lombardini, J.B., and Schaffer, S., eds., Plenum Press.Google Scholar
  6. 6.
    Eppler, B., Wallace, D.R., Pelleymounter, M.A., Booze, R.M., Liu, S., and Dawson, R., 1996, Taurine-dopamine interactions in the striatum, Soc. Neurosci. Abst. 22:1495.Google Scholar
  7. 7.
    Franconi, F., Bennardini, F., Matucci, R., Stendardi, L, Failli, P., Manzini, S., and Giotti, A., 1986, Functional and binding evidence of taurine inhibition of a-adrenoceptor effects on guinea-pig ventricle, J. Mol. Cell. Cardiol., 18:461–468.PubMedCrossRefGoogle Scholar
  8. 8.
    Horikoshi, T., Asanuma, A., Yanagisawa, K., Anzai, K., and Goto, S., 1988, Taurine and β-alanine act on both GABA and glycine receptors in Xenopus oocyte injected with mouse brain messenger RNA, Mol. Brain Res., 4:97–105.CrossRefGoogle Scholar
  9. 9.
    Huxtable, R., 1989, Taurine in the central nervous system and the mammalian actions of taurine, Prog. Neurobiol., 32:471–533.PubMedCrossRefGoogle Scholar
  10. 10.
    Huxtable, R. and Bressler, R., 1973, Effect of taurine on a muscle intracellular membrane, Biochim. Biophys. Acta, 323:573–583.PubMedCrossRefGoogle Scholar
  11. 11.
    Kontro, P., and Oja, S.S., 1990, Interactions of taurine with GABAB binding sites in mouse brain, Neuropharmacology, 29:243–247.PubMedCrossRefGoogle Scholar
  12. 12.
    Lopez-Colome A and Fragoso, G., 1995, Glycine stimulation of glutamate binding to chick retinal pigment epithelium, Neurochem. Res., 20:887–894.PubMedCrossRefGoogle Scholar
  13. 13.
    Medina, J.H. and De Robertis, E., 1984, Taurine modulation of the benzodiapzepine-γ-aminobutyric acid receptor complex in brain membranes, J. Neurochem., 42:1212–1217.PubMedCrossRefGoogle Scholar
  14. 14.
    Nakashima, T., Shima, T., Sakai, M., Yama, H., Mitsuyoshi, H., Inaba, K., Matsumoto, N., Sakamoto, Y., Kashima, K., and Nishikawa, H., 1996, Evidence of a direct action of taurine and calcium on biological membranes, Biochem. Pharmacol., 52:173–176.PubMedCrossRefGoogle Scholar
  15. 15.
    Quinn, M.R. and Miller, C.L., Taurine allosterically modulates flunitrazepam binding to synaptic membranes, J. Neurosci. Res., 33:136-141.Google Scholar
  16. 16.
    Quinn, M.R. and Harris, C.L., 1995, Taurine allosterically inhibits binding of [35S]-t-butylbicyclo-phosphorothionate (TBPS) to rat brain synaptic membranes, Neuropharmacology, 34:1607–1613.PubMedCrossRefGoogle Scholar
  17. 17.
    Saransaari, P. and Oja, S.S., 1993, Phencyclidine-binding sites in mouse cerebral cortex during development and ageing: effects of inhibitory amino acids, Mech. Ageing Dev., 68:125–136.PubMedCrossRefGoogle Scholar
  18. 18.
    Schmieden, V., Kuhse, J., and Betz, H., 1992, Agonist pharmacology of neonatal and adult glycine receptor a subunits: identification of amino acid residues involved in taurine activation, EMBO J., 11:2025–2032.PubMedGoogle Scholar
  19. 19.
    Wallace, D.R. and Booze, R.M., 1995, The dopamine D3-selective radioligand, [3H]-7-OH-DPAT, identifies sigma receptors in rat basal forebrain, J. Neurochem., 64:700–710.PubMedCrossRefGoogle Scholar
  20. 20.
    Wallace, D.R. and Booze, R.M., 1997, Upregulation of (+)-7-hydroxy-N,N-di-n-[3H]propylaminotetralin binding following intracerebroventricular administration of nitric oxide generator, Neurochem. Res., 22:163–170.PubMedCrossRefGoogle Scholar
  21. 21.
    Williams, M., Risley, E.A., and Totaro, J.A., 1980, Interaction of taurine and β-alanine with central nervous system neurotransmitter receptors, Life Sci., 26:557–560.PubMedCrossRefGoogle Scholar
  22. 22.
    Wright, C.E., Tallan, H.H., and Lin, Y.Y., 1986, Taurine: biological update, Ann. Rev. Biochem., 55:427–453.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Pattie Green
    • 1
  • Ralph DawsonJr.
    • 1
  • David R. Wallace
    • 2
  • Jeannie Owens
    • 2
  1. 1.Department of PharmacodynamicsUniversity of FloridaGainesvilleUSA
  2. 2.Department of Pharmacology and PhysiologyOklahoma State UniversityTulsaUSA

Personalised recommendations